Paraplegics who can use their arms but are unable to walk will be among the first group of patients to receive the world’s first federally approved trial using controversial human embryonic stem cells.

Geron Corporation (Nasdaq:GERN) today commented on the impact of recent advances in cellular reprogramming on the development of human embryonic stem cell (hESC)-based therapies.

Geron and Immunomic Therapeutics have reported a patent license agreement under which Geron will receive rights to the LAMP antigen targeting sequence for use in cancer vaccines.

Geron Corporation (Nasdaq: GERN) announced today the appointment of Charles J. Homcy, M.D., to its board of directors. Dr.